Scientists from the Center for Eye Research Australia found that vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma.
The research is published in Clinical & Experimental Ophthalmology and was conducted by Jonathan Crowston et al.
Glaucoma is the world’s leading cause of irreversible blindness, affecting more than 60 million people worldwide.
The disease, which leads to vision loss when cells in the optic nerve and retina are lost, is usually treated with eye drops or surgery to reduce eye pressure.
However, there are currently no treatments to protect cells from further damage or to improve cell function.
In the study, the team found a big improvement in the visual function of glaucoma patients who received a daily high dose of 3 grams of nicotinamide for 12 weeks in addition to their regular treatment to reduce eye pressure.
They followed 57 patients, all of whom received both placebo and vitamin B3 over the course of the study.
The team found that in some people, high-dose nicotinamide significantly improved how nerve cells were functioning in the eye.
This is the first time scientists found that daily high doses of vitamin B3 can lead to early and significant improvements in patients who are also receiving traditional treatments to lower eye pressure.
Researchers say that as a safe therapy that is well tolerated by patients, vitamin B3 has the potential as a clinical supplement to support patients who are receiving glaucoma treatment.
They will assess whether these improvements can help reduce disease progression over a longer period.
If you care about supplements, please read studies that vitamin C could help treat heart rhythm problem, and new supplements can boost strength and cognition in older people.
For more information about supplements, please see recent studies about vitamin that is critical for cancer prevention, and results showing this vitamin may help fight COVID-19, reduce inflammation.
Copyright © 2022 Knowridge Science Report. All rights reserved.
